GENEART Receives Major Contract from Max Planck Institute for Molecular Genetics within the BMBF Joined Project "IG Mutanom"
GENEART AG received a major order from the Max Planck Institute (MPI) for Molecular genetics. GENEART will produce the required genes and gene variants for the project "Mutanom - systems biology of Genetic Diseases" funded by the BMBF (Federal Ministry of education and Research) over the next two years. The expected order volume will be around EUR 300,000.
Goal of the Mutanom project, which includes the Max Planck Institute for Molecular Genetics, the German Cancer Research Center and the Max Delbrück Center for Molecular Medicine as well as partners with expertise in the area of clinical development, is to research the effects of variations (mutations) in the human genotype. For their research the project partners require a large number of gene variants, which will be rationally designed and then produced by GENEART. Initially, project research will concentrate on those mutations, which are known to be relevant to certain diseases, i.e. cancer. The knowledge gained is then expected to be used directly for the development of innovative diagnostic and treatment strategies. The Mutanom Project is an integrated network of the medical genome research, which is financed by the National Genome Research Network.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
